Axogen Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
49.5%projected annual EPS growth
Analyst Coverage
9analysts covering
FY Revenue (est.)
$279.6Mnext fiscal year
FY EPS (est.)
$0.46next fiscal year
Monitoring Framework
Key Performance Indicators
Quarterly Revenue Growth Quarterly2,660.0%Target: At least 20% for FY 2026
Gross Margin Quarterly7,520.0%Target: 74% to 76% for FY 2026
Free Cash Flow AnnuallyTarget: Positive for FY 2026
Watch Items
- Avance Nerve Graft Biologics TransitionTrigger: Commercial availability of BLA-approved Avance early in Q2 2026Action: Monitor transition from human tissue product (Section 361 HCT/P) to licensed biologic product (Section 351 PHS Act) and track post-marketing comparative study against nerve autograft.
- Reimbursement and Payer Coverage ExpansionTrigger: Aetna final reimbursement decisionAction: Track coverage decisions from major commercial insurers and CMS outpatient rate implementation to gauge impact on procedure volumes and contracting.
Research as of 20 Jun 2026